|
|
Article: Study: Actonel Reduces Vertebral Fracture Risk 70% In Patients On Steroids.
- Article from:
- Immunotherapy Weekly
- Article date:
- November 14, 2001
CopyrightCOPYRIGHT 2001 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2001 NOV 14 - (NewsRx.com & NewsRx.net) -- Vertebral fracture risk in men and women who take oral glucocorticoid treatment (>7.5 mg/day prednisone or equivalent) for chronic diseases is significantly reduced with Actonel (risedronate sodium tablets) 5 mg in just one year, according to data presented at the 66th Annual Scientific Meeting of the American College of Gastroenterology in Las Vegas.
Patients on Actonel 5 mg daily while initiating or continuing glucocorticoid (a class of steroids) therapy experienced significant vertebral fracture reduction of 70% compared with placebo (p=0.01, absolute risk reduction 10.8%) within just one year. All patients received ...
Related newspaper, magazine, and journal articles:
|
|
Article: P&G, Sanofi switch Actonel work to Omnicom ...
Medical Marketing & Media;
August 1, 2006 ;
700+ words
... ... involving DTC ads for both Actonel and its archrival draws ... Sanofi-Aventis switched Actonel to an integrated team ... following a review. DDB New York now leads consumer marketing ... will work with the Actonel sales training organization ... s Grey Worldwide in New York, which ...
|
|